Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing May 9, 2024.
- Instrument
- convertible notes
- Principal
- $500,000
- Counterparty
- Juvenescence Limited
- Maturity
- May 9, 2024
- Event
- incurrence
Exact text from the filing
On February 13, 2024, AgeX drew $500,000 of its credit available from Juvenescence under the Secured Note. The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be May 9, 2024.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Serina Therapeutics, Inc. amended Sixth Amendment to Amended and Restated Convertible Promissory Note with Juvenescence Limited (effective 2024-02-09).
- Action
- amendment
- Agreement
- notes offering
- Counterparty
- Juvenescence Limited
- Effective
- 2024-02-09
Exact text from the filing
On February 9, 2024, AgeX and Juvenescence Limited (“Juvenescence”) executed a Sixth Amendment to Amended and Restated Convertible Promissory Note (the “Amendment”) that extends to May 9, 2024 the “Repayment Date” on which the outstanding principal balance and accrued loan origination fees will become due and payable pursuant to the Amended and Restated Secured Convertible Promissory Note, dated February 9, 2023, as previously amended, modified, and restated (the “Secured Note”).
View on SEC.gov